(Q37364295)

19 August 2017

1 reference

title

New and investigational triazole agents for the treatment of invasive fungal infections (English)

1 reference

invasive fungal infections

19 August 2017

main subject

1 reference

De Sarro A

1

1 reference

19 August 2017

La Camera E

series ordinal

2

1 reference

19 August 2017

Fera MT

series ordinal

3

1 reference

19 August 2017

publication date

1 December 2008

1 reference

19 August 2017

published in

Journal of Chemotherapy

1 reference

19 August 2017

volume

20

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

661-671

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Assessing risk factors for systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

History of the development of azole derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

New and emerging treatments for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Recent advances in antifungal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

New investigational antifungal agents for treating invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Management of systemic fungal infections: alternatives to itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Molecular aspects of azole antifungal action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Voriconazole potentiates warfarin‐induced prothrombin time prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Complexity of interactions between voriconazole and antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Interaction between voriconazole and tacrolimus in a kidney-transplanted patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Periorbital zygomycosis (mucormycosis) treated with posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

Emerging azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.6.661

10.1179/JOC.2008.20.6.661

21 January 2018

Identifiers

DOI

0 references

1 reference